Coronary Artery Disease
Conditions
Interventions
Case series:PharmacoinvasiveTherapy with Prourokinase
Sponsors
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. ST segment elevation >= 0.1mv in two or more limb leads, or ST segment elevation >= 0.2mv in two or more adjacent chest leads, or new complete left (or right) bundle branch block; 2. Patients with persistent ischemic chest pain >= 30 minutes and <= 12 hours or onset time of 12-24 hours, such as STEMI patients with progressive ischemic chest pain or hemodynamic instability and continuous ST segment elevation; 3. Patients with STEMI who plan to receive thrombolytic therapy with recombinant human prourokinase for injection (prourokinase); 4. Patients who agree to participate in the clinical trial and sign the written informed consent before operation.
Exclusion criteria
Exclusion criteria: 1. Subjects with non ST segment elevation acute myocardial infarction or unstable angina pectoris; 2. Pregnant, lactating and menstrual women; 3. Hemorrhagic stroke occurred at any time in the past and ischemic stroke occurred within 6 months Or cerebrovascular events; 4. Patients with severe progressive diseases (such as malignant tumor) or diseases with poor prognosis that make patients extremely exhausted; 5. Patients with active visceral bleeding within 4 weeks (e.g. gastrointestinal and urogenital bleeding, but less than 3 months) (except for menstruation), or with incurable peptic ulcer; 6. Patients with intracranial tumor, suspected aortic dissection, arteriovenous malformation and aneurysm; 7. After active antihypertensive treatment, the blood pressure of patients with hypertension was still >= 180 / 110mmhg Diastolic blood pressure (one of which meets this blood pressure standard) 8. Patients who are currently using therapeutic doses of oral anticoagulants, such as warfarin 9. Patients with known bleeding tendency (hemostasis or coagulation dysfunction); 10. Patients with recent (within 6 months) history of craniocerebral or spinal surgery; 11. Subjects with a history of trauma within 2 months, including traumatic cardiopulmonary resuscitation or long-term (>= 10 min) cardiopulmonary resuscitation, or having undergone major surgery; subjects with a history of head trauma within 6 months 12. The patients who had received the puncture of the great vessels in the area that could not be compressed within 2 weeks; 13. Patients with high suspicion of left intracardiac thrombosis (such as mitral stenosis and atrial fibrillation), stent thrombosis 14. Patients with history of fundus hemorrhage caused by diabetes or other diseases; 15. Patients with a history of severe liver and kidney dysfunction (ALT >= 3 times the upper limit of normal; creatinine >= 225 µ mol / L); 16. Patients with shock; 17. Infective endocarditis, acute myocarditis, acute pericarditis, septic thrombophlebitis; Patients with arteriovenous fistula at the site of severe infection; 18. Reinfarction patients with the same location as before; 19. Subjects participating in other interventional clinical trials; 20. Other diseases and conditions not suitable for intravenous thrombolysis are considered by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MACCE adverse clinical events; | — |
Countries
China
Contacts
Public ContactLikun Ma
The First Affiliated Hospital of China University of science and Technology (Anhui Provincial Hospital)
Outcome results
None listed